Gerberding Julie L. 4

Accession 0001127602-21-028263

CIK 0000310158other

View on SEC.gov Company Profile

Filed

Nov 2, 8:00 PM ET

Accepted

Nov 3, 4:11 PM ET

Size

21.0 KB

Accession

0001127602-21-028263

Insider Transaction Report

Form 4

Period: 2021-11-01

Merck & Co., Inc.MRK

Gerberding Julie L.

EVP Strat Comm, Gl Pub Policy

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2021-11-01−11,414→ 22,831 total
Exercise: $75.36From: 2021-05-01Exp: 2030-04-30→ Common Stock (11,414 underlying)
Exercise/Conversion
Common Stock
2021-11-01+19,394→ 124,018.138 total
Sale
Common Stock
2021-11-01$87.91/sh−96,270$8,462,682→ 39,162.138 total
Exercise/Conversion
Common Stock
2021-11-01+35,287→ 74,449.138 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-11-01−35,287→ 0 total
Exercise: $62.07From: 2018-05-05Exp: 2027-05-04→ Common Stock (35,287 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2021-11-01−19,394→ 9,698 total
Exercise: $77.62From: 2020-05-03Exp: 2029-05-02→ Common Stock (19,394 underlying)
Exercise/Conversion
Common Stock
2021-11-01+30,175→ 104,624.138 total
Exercise/Conversion
Common Stock
2021-11-01+11,414→ 135,432.138 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-11-01−30,175→ 0 total
Exercise: $56.04From: 2019-05-04Exp: 2028-05-03→ Common Stock (30,175 underlying)

Footnotes (7)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.9050 to $87.9250, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F2]Holdings include shares acquired in dividend reinvestment transactions.
[F3]Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
[F4]The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.
[F5]The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.
[F6]The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
[F7]The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

Merck & Co., Inc.

CIK 0000310158

→

Entity typeother

Related Parties

filerCIK 0001628884

Filing Metadata

Form type: 4
Filed: Nov 2, 8:00 PM ET
Accepted: Nov 3, 4:11 PM ET
Size: 21.0 KB

View on SEC.gov